Journal article
Fusion to Human Serum Albumin Extends the Circulatory Half-Life and Duration of Antithrombotic Action of the Kunitz Protease Inhibitor Domain of Protease Nexin 2
Abstract
BACKGROUND/AIMS: The Kunitz Protease Inhibitor (KPI) domain of protease nexin 2 (PN2) potently inhibits coagulation factor XIa. Recombinant KPI has been shown to inhibit thrombosis in mouse models, but its clearance from the murine circulation remains uncharacterized. The present study explored the pharmacokinetic and pharmacodynamic effects of fusing KPI to human serum albumin (HSA) in fusion protein KPIHSA.
METHODS: Hexahistidine-tagged KPI …
Authors
Sheffield WP; Eltringham-Smith LJ; Bhakta V
Journal
Cellular Physiology and Biochemistry, Vol. 45, No. 2, pp. 772–782
Publisher
Karger Publishers
Publication Date
2018
DOI
10.1159/000487168
ISSN
1015-8987
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Amyloid beta-Protein PrecursorAnimalsArea Under CurveBlood Coagulation FactorsChloridesChromatography, High Pressure LiquidDisease Models, AnimalFerric CompoundsHalf-LifeHistidineHumansIodine RadioisotopesMiceOligopeptidesProtein DomainsROC CurveReceptors, LDLRecombinant Fusion ProteinsSerum Albumin, HumanSpectrometry, Mass, Electrospray IonizationThrombosis